170 related articles for article (PubMed ID: 37279357)
1. HER2-Targeted Therapy Shows Promise across Tumor Types.
Cancer Discov; 2023 Aug; 13(8):OF3. PubMed ID: 37279357
[TBL] [Abstract][Full Text] [Related]
2. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
Rolfo C; Del Re M; Russo A
Clin Cancer Res; 2023 Nov; 29(21):4317-4319. PubMed ID: 37656059
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Agnostic Treatment Heading to the Clinic?
Cancer Discov; 2023 Dec; 13(12):OF10. PubMed ID: 37888905
[TBL] [Abstract][Full Text] [Related]
4. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
Jørgensen JT
Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
Makhlin I; DeMichele A
Cell Rep Med; 2022 Jun; 3(6):100668. PubMed ID: 35732147
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
8. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
Ali A; Graff SL
Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
10. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
[TBL] [Abstract][Full Text] [Related]
12. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S; Bešlija S; Gatalica Z
Bosn J Basic Med Sci; 2021 Feb; 21(1):1-4. PubMed ID: 32530388
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
16. T-DXd: New Standard for HER2-Low Breast Cancer.
Cancer Discov; 2022 Aug; 12(8):1828. PubMed ID: 35666611
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
Neupane N; Thapa S; Bhattarai A; Ahuja K; Schlam I; Mittal A; Tolaney SM; Tarantino P
Curr Oncol Rep; 2023 Dec; 25(12):1467-1482. PubMed ID: 37938529
[TBL] [Abstract][Full Text] [Related]
19. Metastatic
Yun KM; Bazhenova L
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
